MedTrace Logo

Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)

NCT01267422 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2018-01-31

Study results available
· View outcomes & findings →

Summary

This study is meant to assess the safety and efficacy of rAAV2-ND4 treatment of Leber hereditary optic neuropathy with 11778 LHON mutation.

Conditions

  • Leber Hereditary Optic Neuropathy

Interventions

DRUG

rAAV2-ND4

injection

Sponsors & Collaborators

  • Huazhong University of Science and Technology

    collaborator OTHER

  • Bin Li

    lead OTHER

Principal Investigators

  • bin Li, PhD,MD · Deputy Director of Ophthalmology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
8 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01267422 on ClinicalTrials.gov